Action by FDA ensures trial sponsors must consider diversity

Pharma has recognised that there is a problem with diversity in clinical trials, but has so far struggled to successfully achieve real change. Ben Hargreaves covers how the US FDA has updated its guidance documents to demand that trial sponsors must make diversity a part of their planning.